Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Sickle Cell Disease Therapeutics Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Sickle Cell Anemia
  • 1.3.3 Sickle Beta Thalassemia
  • 1.3.4 Sickle Hemoglobin C Disease
• 1.4 Market Segment by Application
  • 1.4.1 Global Sickle Cell Disease Therapeutics Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Clinics
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Sickle Cell Disease Therapeutics Market Size
  • 2.1.1 Global Sickle Cell Disease Therapeutics Revenue 2014-2025
  • 2.1.2 Global Sickle Cell Disease Therapeutics Sales 2014-2025
• 2.2 Sickle Cell Disease Therapeutics Growth Rate by Regions
  • 2.2.1 Global Sickle Cell Disease Therapeutics Sales by Regions 2014-2019
  • 2.2.2 Global Sickle Cell Disease Therapeutics Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Sickle Cell Disease Therapeutics Sales by Manufacturers
  • 3.1.1 Sickle Cell Disease Therapeutics Sales by Manufacturers 2014-2019
  • 3.1.2 Sickle Cell Disease Therapeutics Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Sickle Cell Disease Therapeutics Revenue by Manufacturers (2014-2019)
  • 3.2.2 Sickle Cell Disease Therapeutics Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Sickle Cell Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
• 3.3 Sickle Cell Disease Therapeutics Price by Manufacturers
• 3.4 Key Manufacturers Sickle Cell Disease Therapeutics Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Sickle Cell Disease Therapeutics Market
• 3.6 Key Manufacturers Sickle Cell Disease Therapeutics Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Sickle Cell Anemia Sales and Revenue (2014-2019)
  • 4.1.2 Sickle Beta Thalassemia Sales and Revenue (2014-2019)
  • 4.1.3 Sickle Hemoglobin C Disease Sales and Revenue (2014-2019)
• 4.2 Global Sickle Cell Disease Therapeutics Sales Market Share by Type
• 4.3 Global Sickle Cell Disease Therapeutics Revenue Market Share by Type
• 4.4 Sickle Cell Disease Therapeutics Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Sickle Cell Disease Therapeutics Sales by Application

6 United States

• 6.1 United States Sickle Cell Disease Therapeutics Breakdown Data by Company
• 6.2 United States Sickle Cell Disease Therapeutics Breakdown Data by Type
• 6.3 United States Sickle Cell Disease Therapeutics Breakdown Data by Application

7 European Union

• 7.1 European Union Sickle Cell Disease Therapeutics Breakdown Data by Company
• 7.2 European Union Sickle Cell Disease Therapeutics Breakdown Data by Type
• 7.3 European Union Sickle Cell Disease Therapeutics Breakdown Data by Application

8 China

• 8.1 China Sickle Cell Disease Therapeutics Breakdown Data by Company
• 8.2 China Sickle Cell Disease Therapeutics Breakdown Data by Type
• 8.3 China Sickle Cell Disease Therapeutics Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Sickle Cell Disease Therapeutics Breakdown Data by Company
• 9.2 Rest of World Sickle Cell Disease Therapeutics Breakdown Data by Type
• 9.3 Rest of World Sickle Cell Disease Therapeutics Breakdown Data by Application
• 9.4 Rest of World Sickle Cell Disease Therapeutics Breakdown Data by Countries
  • 9.4.1 Rest of World Sickle Cell Disease Therapeutics Sales by Countries
  • 9.4.2 Rest of World Sickle Cell Disease Therapeutics Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 AstraZeneca
  • 10.1.1 AstraZeneca Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.1.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.1.5 AstraZeneca Recent Development
• 10.2 Eli Lilly
  • 10.2.1 Eli Lilly Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.2.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.2.5 Eli Lilly Recent Development
• 10.3 Novartis
  • 10.3.1 Novartis Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.3.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.3.5 Novartis Recent Development
• 10.4 Pfizer
  • 10.4.1 Pfizer Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.4.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.4.5 Pfizer Recent Development
• 10.5 Baxter
  • 10.5.1 Baxter Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.5.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.5.5 Baxter Recent Development
• 10.6 Emmaus Life Sciences
  • 10.6.1 Emmaus Life Sciences Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.6.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.6.5 Emmaus Life Sciences Recent Development
• 10.7 Bluebird bio
  • 10.7.1 Bluebird bio Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.7.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.7.5 Bluebird bio Recent Development
• 10.8 Blood Therapeutics
  • 10.8.1 Blood Therapeutics Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.8.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.8.5 Blood Therapeutics Recent Development
• 10.9 Sangamo Therapeutics
  • 10.9.1 Sangamo Therapeutics Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.9.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.9.5 Sangamo Therapeutics Recent Development
• 10.10 Acceleron Pharma
  • 10.10.1 Acceleron Pharma Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Sickle Cell Disease Therapeutics
  • 10.10.4 Sickle Cell Disease Therapeutics Product Introduction
  • 10.10.5 Acceleron Pharma Recent Development
• 10.11 Arena Pharmaceuticals
• 10.12 Alnylam Pharmaceuticals

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Sickle Cell Disease Therapeutics Sales Channels
  • 11.2.2 Sickle Cell Disease Therapeutics Distributors
• 11.3 Sickle Cell Disease Therapeutics Customers

12 Market Forecast

• 12.1 Global Sickle Cell Disease Therapeutics Sales and Revenue Forecast 2019-2025
• 12.2 Global Sickle Cell Disease Therapeutics Sales Forecast by Type
• 12.3 Global Sickle Cell Disease Therapeutics Sales Forecast by Application
• 12.4 Sickle Cell Disease Therapeutics Forecast by Regions
  • 12.4.1 Global Sickle Cell Disease Therapeutics Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Sickle Cell Disease Therapeutics Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorderhave atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.
In 2019, the market size of Sickle Cell Disease Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Sickle Cell Disease Therapeutics.

This report studies the global market size of Sickle Cell Disease Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Sickle Cell Disease Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
AstraZeneca
Eli Lilly
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird bio
Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals

Market Segment by Product Type
Sickle Cell Anemia
Sickle Beta Thalassemia
Sickle Hemoglobin C Disease

Market Segment by Application
Hospitals
Clinics
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Sickle Cell Disease Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Sickle Cell Disease Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Sickle Cell Disease Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025